New drug may help 'Hard-to-Transplant' kidney patients stay healthy for years
NCT ID NCT05714514
First seen Nov 18, 2025 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This study follows 64 highly sensitized kidney transplant patients who previously received either the drug imlifidase or standard care to enable transplantation. Researchers will track how many patients are alive and free of dialysis at 3 and 5 years. The goal is to see if imlifidase provides lasting benefits for these hard-to-match patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED PATIENTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Columbia University
New York, New York, 10032, United States
-
Cooperman Barnabas Medical Center
Livingston, New Jersey, 07039, United States
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
John Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Methodist Hospital Specialty and Transplant
San Antonio, Texas, 78229, United States
-
New York University (NYU) Langone Transplant Institute, NYU Langone Health
New York, New York, 10016, United States
-
Northwestern University, Dept. General Surgery, Div. Transplantation
Chicago, Illinois, 60611, United States
-
University of Alabama at Birmingham (UAB) Hospital
Birmingham, Alabama, 35249, United States
-
University of Chicago, Department of Surgery, Clinical Research Center
Chicago, Illinois, 60637, United States
-
University of Washington Medical Center
Seattle, Washington, 98195, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
imlifidase
What this could lead to
If successful, this could confirm that imlifidase helps highly sensitized patients receive a kidney transplant and maintain good long-term outcomes.
What could go wrong
This is a small, non-randomized follow-up study with only 64 participants. Results may not apply to all patients, and long-term risks like graft rejection or infection remain.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.